Actively Recruiting
Phase 2a Randomized Study of ALN-PNP With or Without GLP1R Agonist in Adults With PNPLA3-Related MASLD
Led by Regeneron Pharmaceuticals · Updated on 2026-09-29
204
Participants Needed
9
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of a drug called ALN-PNP, with and without another medication like tirzepatide that controls blood sugar, appetite, and weight, in adults with Metabolic Dysfunction-Associated Steatotic Liver Disease MASLD, also known as fatty liver disease. This Phase 2a trial aims to understand how ALN-PNP impacts the reduction of liver fat and its influence on the body and liver, especially in people with a specific PNPLA3 genetic type. Participants may receive ALN-PNP alone or combined with tirzepatide, or a placebo matching ALN-PNP, all given according to the study plan. The trial has two parts and uses a randomized, double-blind design to compare how well ALN-PNP works with or without tirzepatide. The study includes treatment and monitoring periods lasting up to 48 weeks to assess changes in liver fat and side effects. During the study, participants will undergo regular evaluations including Magnetic Resonance Imaging to measure liver fat, blood tests to check drug levels and liver function, and monitoring for any side effects up to 72 weeks. Researchers will measure the percent change in liver fat at weeks 24 and 48 and observe treatment-emergent adverse events. The full participation period can last up to about 72 weeks, allowing close observation of both the treatment effects and safety.
CONDITIONS
Brief Title
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here